Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 34 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

15%

5 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (3)
Early P 1 (1)
P 1 (4)
P 2 (3)
P 3 (3)
P 4 (2)

Trial Status

Recruiting16
Not Yet Recruiting9
Active Not Recruiting4
Completed2
Enrolling By Invitation1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (34)

Showing 20 of 20 trials
NCT07736586Phase 1Not Yet RecruitingPrimary

A Study of HL40626S Tablets in Healthy Adults

NCT07390487Not ApplicableRecruitingPrimary

The Effects of Audio-Based Therapy on Anxiety in Psoriasis

NCT07642544Not Yet Recruiting

Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis

NCT07635043Phase 4Not Yet RecruitingPrimary

Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis

NCT06905028Not ApplicableActive Not Recruiting

Exploratory Clinical Study on Fasting in Psoriasis and Psoriatic Arthritis (RiseFast)

NCT07634016RecruitingPrimary

Global Healthcare Study on Psoriasis

NCT07455578Phase 1Recruiting

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

NCT07594054Not Yet Recruiting

Inflammation Digital Biomarkers Validation Study

NCT07221890Not ApplicableActive Not Recruiting

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

NCT06846541Phase 3Active Not Recruiting

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT07448337Not Yet Recruiting

Psoriasis Comorbidities at Hospital Calderón Guardia

NCT07448402Not Yet Recruiting

Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease

NCT07255781WithdrawnPrimary

Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

NCT07401992Phase 4RecruitingPrimary

Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

NCT07370766RecruitingPrimary

Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

NCT07351448Not Yet RecruitingPrimary

Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators

NCT07298265RecruitingPrimary

Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis

NCT06982352Phase 1Recruiting

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

NCT07233291Phase 2RecruitingPrimary

A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults

NCT07181343Phase 1CompletedPrimary

A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)

Scroll to load more

Research Network

Activity Timeline